SCHEMBL14132901

SCHEMBL14132901

N=C1NC(=O)/C(=C\c2cn(-c3ccccc3)nc2-c2ccccc2)S1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLK1 P53350 1/20 0.62
NTSR1 P30989 1/20 0.56
MEN1 O00255 3/20 0.55
KMT2A Q03164 3/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
NPSR1 Q6W5P4 2/20 0.55
POLB P06746 2/20 0.55
LMNA P02545 1/20 0.55
MAPT P10636 1/20 0.55
HPGD P15428 1/20 0.55
MAPK1 P28482 1/20 0.55
HTT P42858 1/20 0.55
MCL1 Q07820 1/20 0.55
SAE1 Q9UBE0 1/20 0.55
UBA2 Q9UBT2 1/20 0.55
S1PR4 O95977 1/20 0.55
GAA P10253 1/20 0.55
PKM P14618 1/20 0.55
S1PR1 P21453 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14132896 0.92 SIRT2 (0.63) NTSR1MEN1KMT2ASMN1; SMN2NPSR1
SCHEMBL14132600 0.92 MAPT (0.60) PLK1NTSR1MEN1KMT2ASMN1; SMN2
SCHEMBL14133119 0.92 LMNA (0.58) PLK1MEN1KMT2ASMN1; SMN2NPSR1
SCHEMBL13345210 0.88 PLK1 (0.65) PLK1NTSR1MEN1KMT2ASMN1; SMN2
SCHEMBL14133110 0.87 KMT2A (0.56) MEN1KMT2ASMN1; SMN2NPSR1MAPT
SCHEMBL14133150 0.86 PTGES (0.70) MEN1KMT2ANPSR1HPGDPTGES
SCHEMBL14133112 0.85 MEN1 (0.56) MEN1KMT2ASMN1; SMN2NPSR1POLB
SCHEMBL14133222 0.83 HPGD (0.60) PLK1MEN1KMT2ASMN1; SMN2NPSR1
SCHEMBL14132601 0.83 PTGES (0.57) MEN1KMT2ANPSR1HPGDPTGES
SCHEMBL14133570 0.79 MAPT (0.66) MEN1KMT2ASMN1; SMN2NPSR1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120302581-A1 Methods and Compositions for the Treatment of RAS Associated Disorders THE TRUSTEES OF DARTMOUTH COLLEGE 2012-11-29 US disclosed
US-20120302581-A1 Methods and Compositions for the Treatment of RAS Associated Disorders THE TRUSTEES OF DARTMOUTH COLLEGE 2012-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120302581-A1 Methods and Compositions for the Treatment of RAS Associated Disorders NRAS, HRAS, KRAS PLK1 328/4885NTSR1 2414/4885MEN1 40/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.